Contact this trialFirst, we need to learn more about you.
Alkylating agent
Lurbinectedin + Doxorubicin for Leiomyosarcoma
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is studying if the combination of lurbinectedin with doxorubicin is safe and tolerable in people with soft tissue sarcoma. They will also compare the two to see which is more effective in treating leiomyosarcoma.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.